Zhang Yishan, Hu Jintao, Yang Jingtian, Xie Yingwei, Chen Zhiliang, Shangguan Wentai, Han Jinli, He Wang, Yang Jingyin, Zheng Zaosong, Zhong Qiyu, Zhu Dingjun, Xie Wenlian
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Front Oncol. 2022 Jan 21;12:814512. doi: 10.3389/fonc.2022.814512. eCollection 2022.
Currently, the progress of targeted drugs in the treatment of metastatic clear cell renal cell carcinoma (mccRCC) is limited. Cytoreductive nephrectomy (CN), as an alternative treatment, can improve the prognosis of patients with metastatic renal cell carcinoma to some extent. However, it is unclear which patients would benefit from this tumor reduction operation. As a consequence, we developed a predictive model to identify patients who may well benefit from CN in terms of survival.
We identified patients with metastatic clear cell renal cell carcinoma retrospectively from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015) and classified them into surgery and non-surgery groups. Propensity score matching (PSM) was performed to balance the baseline characteristics. Patients who survived longer than the median overall survival (OS) of no-surgery group were defined as surgical-benefit patients. Then, we developed a predictive model based on preoperative characteristics using multivariable Logistic regression. Calibration curves and the area under the receiver operating characteristic (AUC) were used to evaluate the efficiency of the predictive model. The clinical value of the nomogram was assessed utilizing decision curve analysis (DCA).
Our study collected 5544 patients from the SEER database, with 2352(42.4%) receiving cytoreductive surgery. Overall survival (OS) was longer in the CN group than in the non-surgery group after 1:1 propensity scoring matching (median OS: 19 months vs 7 months; hazard ratio (HR) =0.4106, P< 0.001). In the matched surgery group, 65.7% (367) patients survived more than 7 months after the operation and they were considered to benefit from CN. The predictive model performed well on both the training group (AUC=73.4%) and the validation group (AUC=71.9%) and the calibration curves indicated a high degree of consistency. The decision curve analysis curve demonstrated the clinical utility. We classified surgical patients into the beneficial group and non-beneficial group by using the predictive model, then discovered a substantial difference in OS between the two groups.
We developed a nomogram to select ideal mccRCC patients who might benefit from cytoreductive nephrectomy. Clinicians could make a more precise treatment strategy for mccRCC patients.
目前,靶向药物在转移性透明细胞肾细胞癌(mccRCC)治疗中的进展有限。减瘤性肾切除术(CN)作为一种替代治疗方法,在一定程度上可改善转移性肾细胞癌患者的预后。然而,尚不清楚哪些患者会从这种肿瘤减瘤手术中获益。因此,我们开发了一种预测模型,以识别可能在生存方面从CN中获益的患者。
我们从监测、流行病学和最终结果(SEER)数据库(2010 - 2015年)中回顾性识别转移性透明细胞肾细胞癌患者,并将他们分为手术组和非手术组。进行倾向评分匹配(PSM)以平衡基线特征。存活时间超过非手术组中位总生存期(OS)的患者被定义为手术获益患者。然后,我们使用多变量逻辑回归基于术前特征开发了一种预测模型。校准曲线和受试者操作特征曲线下面积(AUC)用于评估预测模型的效率。利用决策曲线分析(DCA)评估列线图的临床价值。
我们的研究从SEER数据库中收集了5544例患者,其中2352例(42.4%)接受了减瘤性手术。在1:1倾向评分匹配后,CN组的总生存期(OS)长于非手术组(中位OS:19个月对7个月;风险比(HR)=0.4106,P<0.001)。在匹配的手术组中,65.7%(367例)患者术后存活超过7个月,他们被认为从CN中获益。预测模型在训练组(AUC = 73.4%)和验证组(AUC = 71.9%)中均表现良好,校准曲线显示出高度一致性。决策曲线分析曲线证明了其临床实用性。我们使用预测模型将手术患者分为获益组和非获益组,然后发现两组之间的OS存在显著差异。
我们开发了一种列线图,以选择可能从减瘤性肾切除术中获益的理想mccRCC患者。临床医生可为mccRCC患者制定更精确的治疗策略。